Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01221571 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
A Phase 1 study of Hodgkin Lymphoma, sponsored by Affimed.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 3
- Study locations
NCT01221571: Completed Phase 1 study of Hodgkin Lymphoma, sponsored by Affimed.
NCT01221571 is a Phase 1 study of Hodgkin Lymphoma that has completed, run by Affimed. The registered enrollment target is 28 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01221571, a Phase 1 study of Hodgkin Lymphoma, has completed, sponsored by Affimed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.
Primary Outcome
Measure occurrence of adverse events and monitor laboratory safety parameters. Immunogenicity of AFM13.
Conditions Studied
Interventions
- DRUG AFM 13
Study Locations (3)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Köln
- University Hosptial Cologne - Cologne
Other
- University Hospital Würzburg - Würzburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
What the finished NCT01221571 record still lists
NCT01221571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AFM 13 is the first listed.
NCT01221571 reports a single indexed study location in Texas, Köln, Other.
Frequently Asked Questions
What is clinical trial NCT01221571 about?
NCT01221571 is a clinical study titled "A Study to Assess AFM13 in Patients With Hodgkin Lymphoma". The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.
What is the current status of trial NCT01221571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2010-10. Estimated completion is 2013-06.
What conditions does trial NCT01221571 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT01221571?
The interventions under investigation include: AFM 13 (DRUG).
Who is sponsoring clinical trial NCT01221571?
This trial is sponsored by Affimed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01221571 being conducted?
This trial has 3 study locations across Texas, Köln. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01221571's enrollment target sits among peer trials
28 54th of 71 higher than 18 of 71 other Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
-
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia